Abstract Purpose of Review Immune checkpoint inhibitors (ICIs) have improved the survival
of several cancers. However, they may cause a wide range of immune-related adverse …

Chimeric antigen receptor (CAR)-T cell therapy is effective in the treatment of
refractory/relapsed (r/r) hematological malignancies (r/r B-cell lymphoblastic leukemia, B-cell …

Cancer treatment is associated with various side effects of antitumor agents, which increase
the morbidity and mortality of these patients. Cardiovascular complications are considered to …

The advancement in therapy has provided a dramatic improvement in the rate of recovery
among cancer patients. However, this improved survival is also associated with enhanced …

Simple Summary Immune checkpoint inhibitors (ICIs) are novel cancer therapeutics that
address the immune system to attack malignancies. While this therapy has significantly …

Chimeric antigen receptor T-cells (CAR-T) are improving outcomes in pediatric and adult
patients with relapsed or refractory B-cell acute lymphoblastic leukemias and subtypes of …

Immune checkpoint inhibitors (ICIs) targeting programmed cell death 1, programmed cell
death ligand 1, and cytotoxic T lymphocyte-associated antigen-4 have shown significantly …

Simple Summary Immune checkpoint inhibitors, including monoclonal antibodies directed
against the programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) …

Throughout the last decades, newly developed chemotherapeutic agents and
immunotherapies that target signaling pathways have provided patients with better …

The field of malignant hematology is transforming with novel immunotherapeutic
approaches. Unfortunately, quality of life, treatment efficacy, and life expectancy are …